|
【结 构 式】 
|
【分子编号】52940 【品名】methyl (1R,2S,3S,5S)-3-(4-fluorophenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate 【CA登记号】n/a |
【 分 子 式 】C15H18FNO2 【 分 子 量 】263.3118632 【元素组成】C 68.42% H 6.89% F 7.22% N 5.32% O 12.15% |
合成路线1
该中间体在本合成路线中的序号：(V)Addition of tributyltin hydride to the triple bond of propargyl alcohol (I) in the presence of AIBN provided a mixture of (Z)-(II) and (E)-3-(tributylstannyl)-2-propen-1-ol (III), which were separated by column chromatography. The desired (E)-allyl alcohol (III) was further converted to the corresponding chloride (IV) by treatment with PPh3 in refluxing CCl4. Alkylation of the nortropane derivative (V) with chloride (IV) in the presence of celite-supported KF furnished the N-(tributylstannyl)propenyl nortropane (VI). The target iodinated compound was then prepared by treatment of (VI) with N-iodosuccinimide.
| 【2】 Elmaleh, D.R.; Madras, B.K.; Meltzer, P.; Hanson, R.N. (General Hospital Corporation; Harvard College; Northeastern University); Substd. 2-carboxyalkyl-3-(fluorophenyl)-8-(3-haloprofen-2-yl) nortropanes and their use as imaging agents for neurodegenerative disorders. EP 0734385; EP 1081147; WO 9511901 . |
| 【1】 Elmaleh, D.R.; et al.; Preparation and biological evaluation of iodine-125-IACFT: A selective SPECT agent for imaging dopamine transporter sites. J Nucl Med 1996, 37, 7, 1197. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 16664 | Propargyl Alcohol; 2-propyn-1-ol | 107-19-7 | C3H4O | 详情 | 详情 |
| (II) | 52939 | (Z)-3-(tributylstannyl)-2-propen-1-ol | C15H32OSn | 详情 | 详情 | |
| (III) | 52942 | (E)-3-(tributylstannyl)-2-propen-1-ol | n/a | C15H32OSn | 详情 | 详情 |
| (IV) | 50995 | tributyl[(E)-3-chloro-1-propenyl]stannane | C15H31ClSn | 详情 | 详情 | |
| (V) | 52940 | methyl (1R,2S,3S,5S)-3-(4-fluorophenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate | n/a | C15H18FNO2 | 详情 | 详情 |
| (VI) | 52941 | methyl (1R,2S,3S,5S)-3-(4-fluorophenyl)-8-[(E)-3-(tributylstannyl)-2-propenyl]-8-azabicyclo[3.2.1]octane-2-carboxylate | n/a | C30H48FNO2Sn | 详情 | 详情 |